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INTRODUCTION
Mephedrone and MDPVare both b-ketophenethylamine
derivatives of cathinone, a compound isolated from the East
African plant Catha edulis (khat, qat). Mephedrone is
commonly referred to as plant food, MCAT, 4-MMC, meow
meow, meph, and drone; MDPV is commonly called MTV,
MDPK, Magic, and Super Coke. Both are structurally similar
to amphetamines, with mephedrone sharing close similarities
with methamphetamine and MDPV with ecstasy (3,4-
methylenedioxymethamphetamine; MDMA). Bath salts pose
an increasing public health risk in the United States, with
reports of toxicity and mortality increasing along with calls to
poison centers throughout the United States. Packages labeled
with innocuous monikers such as White Ice, Ivory Wave, Ocean
Snow, Lunar Wave, and Vanilla Sky intentionally belie the
dangerous substances within, which are by no means intended
to replace legitimate bath products. The white or tan crystalline
powder commonly is administered by nasal insufﬂation or oral
ingestion; however, rectal suppository and less commonly,
intramuscular or intravenous injection, are also reported.
1,2
A movement to ban these substances is growing in the
United States, following similar actions in Europe.
3 Although
successfully outlawed in some locales, this movement has not
eliminated the public health hazards posed by mephedrone or
MDPV. Emergency physicians (EP) should thus be
knowledgeable in the epidemiology of bath salt abuse, the
clinical toxidrome with which bath salt toxicity presents, and
appropriate treatment strategies to reduce morbidity and
mortality in patients presenting with bath salt toxicity.
CLINICAL EFFECTS
Based on studies of similar compounds, mephedrone and
MDPV may possess intrinsic stimulant properties owing to
their effects on plasma membrane dopamine, norepinephrine,
and serotonin transporters, resulting in both reuptake inhibition
and direct agonist activity.
1,4,5 The exact action of mephedrone
and MDPV remains somewhat theoretical, as previously tested
compounds have demonstrated varying effects despite their
structural similarities. Norepinephrine and dopamine reuptake
inhibition are likely prominent in MDPVand mephedrone,
resulting in a sympathomimetic toxidrome similar to that of
more familiar illicit substances with which most providers are
more familiar, including cocaine, methamphetamine, and
ecstasy.
6
User reports describe a euphoric high lasting between 2 to
4 hours with prominent letdown effects lasting several hours
afterward. Reported doses range from 5 to 10 mg for the more
lipophilic MDPV (although 1 patient reported taking 2 g over
an unclear time course) and 100 to 500 mg for mephedrone.
7–10
Redosing of both is common. Euphoria, empathic mood, sexual
stimulation, subjectively greater mental focus, and increased
energy are reported in the highs of both substances.
1,7,8 In a
recent survey study of past mephedrone users, the 1,506
participants revealed that ecstacy compared most similarly.
Signiﬁcant complications have also been documented,
including seizure activity, severe agitation, myocarditis, and
chest pain, as well as compulsive dosing to sustain effect.
8,11–13
Case fatalities resulting from bath salt consumption, as well as
consumption of mephedrone and MDPV from other sources,
have also been published in the literature.
11,14–16
Some of the reported cases can shed light on the speciﬁc
clinical manifestations.
A 36-year-old male in the Netherlands became acutely
agitated and enraged after ingesting mephedrone along with
cocaine, and subsequently lost consciousness and died despite
resuscitation efforts.
16 A 29-year-old male found unresponsive
at a nightclub died of cerebral edema and brainstem herniation.
Qualitative toxicologic blood screening revealed mephedrone,
and no other substance, in his blood.
11 Serum sodium was
noted to be 125 mmol/L, later suggested by laboratory data to
have resulted from water intoxication. The ﬁrst synthetic
cathinone-related death in the United States, described in the
scientiﬁc literature, involved a 22-year-old malewhowas found
unresponsive and subsequently died at the receiving hospital.
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14 One case of
mephedrone-related myocarditis has also been reported in the
literature.
13 In this instance, a 19-year-old male presented with
crushing chest pain after ingesting mephedrone sold as ‘‘not-
for-human-consumption’’ plant food. Electrocardiographic
changes with greater than 3 mm ST-segment elevation in the
anterolateral leads, and high T2 signal at the lateral left
ventricle on cardiac magnetic resonance imaging, conﬁrmed
the diagnosis of myocarditis. One additional case of
documented 2-mm ST depression in a patient exposed to
MDPVis reported, although this case did not result in death and
resolved with only sublingual nitrates.
10 MDPV was implicated
by history, though never analytically conﬁrmed, to be the cause
of the death of a 24-year-old man reported by the lay press.
17 A
recent series of cases of analytically conﬁrmed mephedrone
toxicity veriﬁed the sympathomimetic toxidrome that
accompanies its use and provided insight into the spectrum of
care and disposition undertaken for acute mephedrone toxicity.
Among these cases were 4 emergency-department (ED) and
short-stay discharges, 2 ward admissions, and 1 intensive care
unit admission/subsequent death, reported in 7 cases.
11
SCOPE OF THE PROBLEM
Rising use patterns and cases of self-mutilation and suicide
have garnered increasing media attention.
18 A recent survey of
young adult ‘‘clubbers’’ in England revealed that 33.6% of
respondents had used mephedrone in the past month, nearing
the last-month use of cocaine, MDMA, and ketamine. More
than 40% of respondents reported ever having used
mephedrone.
19 While reports of deaths due to mephedrone and
MDPV consumption litter popular media outlets, several have
also been reported in the scientiﬁc literature.
20–22 In a case
series of 4 fatalities in Scotland in which mephedrone was
detected in postmortem femoral blood samples, 2 of the deaths
were ofﬁcially attributed to mephedrone toxicity, 1 was
attributed to an abdominal stab wound, and another was not
described. In 2 of the 4 cases, b-keto amphetamines were not
suspected but found on gas chromatography-mass
spectrometry; multiple coingestants were identiﬁed in 3 of the
cases.
23 As with other sympathomimetic drugs of abuse, the
morbidity and mortality associated with bath salts stem both
from direct physiologic toxicity and from behaviors spurred by
the drugs’ effects.
Incident usage of cathinone-derived sympathomimetic
bath salts continues to increase in the United States. Data are
limited, largely because unique surveillance coding of bath salt
calls to poison centers was initiated only in mid 2010 (Bailey,
personal communication, April 25, 2011). Nationally, 302 calls
regarding bath salts were made to poison centers in 2010; by
October 3, a total of 5,226 calls to poison centers had already
been made in 2011 (Bailey, personal communication, October
3, 2011).
24,25 These data represent all calls made to US poison
centers during the described time periods, and certainly
represent a small slice of all bath salt use and morbidity in the
United States. By contrast, poison center calls referencing
synthetic cannabinoids have not seen the same increase in
volume. This is a comparison that may prove instructive for
EPs: the designer synthetic marijuana movement is of similar
scope, likely familiar to most EPs, and it seems to be on the
decline, while bath salt use seems to be on the rise (see
Figure).
26
On September 7, 2011 the US Drug Enforcement Agency
(DEA) announced that it will exercise its emergency scheduling
authority and temporarily control MDPVand mephedrone
(along with methylone, a similar compound), as schedule I
substances for a minimum of 12 months.
27 Senator Charles
Schumer (D, New York), who had introduced legislation in
February 2011 that urged deﬁning both as schedule I controlled
substances, now reports that he will pursue permanent
scheduling.
28–30 The DEA considers both MDPVand
mephedrone analogs of methcathinone, a schedule I substance,
and thus covered by the Federal Analogue Act, but only if
intended for human consumption. At the time of the DEA’s
announcement, at least 33 states had independently taken
measures to control the substances speciﬁcally in bath salts.
27–35
Some have suggested that scheduling these new ‘‘legal
highs’’ has little effect on actual control of the substance, and
that the shift from ‘‘legal’’ to illegal may result in increased
risks for users owing to the possibility of adulterated
manufacturing and reliance on street dealers.
36,37 The results of
previous bans on mephedrone suggest a dim end to the battle to
reduce its use through legal actions. One instructive example of
this is the ban on mephedrone enacted in the United Kingdom
on April 16, 2010.
38 A study of national poison center data in
the year leading up to the ban revealed roughly 1,800 contacts
with mephedrone-poisoned patients, incrementally increasing
month by month.
39 A survey completed 3 months after banning
the substance, including 150 previous mephedrone users,
demonstrated that two thirds of users continued using the drug
despite its illegality.
36
SUGGESTED EVALUATION AND MANAGEMENT
Speciﬁc recommendations for ED evaluation and
management of isolated bath salts exposures, speciﬁcally for
mephedrone or MDPV, would be difﬁcult in most cases
presenting to the ED, and interventions typically undertaken for
more common sympathomimetic toxicities remain the ﬁrst line
of therapy. A speciﬁc antidote does not exist, and few
laboratories have the capacity to screen serum or urine for
speciﬁc bath salts; to our knowledge, none on a timeline useful
in the acute care setting. Features typical of the bath salt
toxidrome include, but are not limited to, altered mentation and
sensorium, agitation, tachycardia, hypertension, and
hyperthermia, with other symptoms possible as well. Such a
presentation is not onlycommon but also consistent with awide
range of disease states, both toxicologic and nontoxicologic.
Even among patients with unequivocally toxicologic etiologies
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of potential intoxicants and diagnoses, including serotonin
syndrome, neuroleptic malignant syndrome, anticholinergic
and sympathomimetic toxidromes, drug withdrawal syndrome,
and exposure to older hallucinogens (ie, lysergic acid
diethylamine, phencyclidine) or to a newer tryptamine or
phenethylamine hallucinogen. At the moment, it remains
advisable to keep designer b-ketophenethylamine cathinone
derivatives such as mephedrone and MDPVon the differential
diagnosis for patients presenting with the symptoms listed
above or with toxidromes largely consistent with
sympathomimetic toxicity.
Clinical experience in the treatment of bath salt toxicity is
limited, and stratifying risk for certain outcomes that draw
concernwith other sympathomimetics or with new independent
concerning outcomes is difﬁcult. The risk for acute coronary
syndrome, rhabdomyolysis, and serotonin syndrome, for
example, remains unclear at this time, as does the subsequent
need for laboratory testing and appropriate monitoring
parameters. The case reports discussed above document
important outcomes including death, myocarditis, agitated
delirium, and hyponatremia, all of which merit considerable
care in the management of documented or suspected bath salt
toxicity. It thus seems prudent to include in the ED workup
several key monitoring and therapeutic interventions.
Peripheral intravenous access and cardiac monitoring are
essential starting points, as is obtaining full vital signs at the
outset of the visit including temperature, and repeating those
vital signs during the ED stay. We recommend, at minimum,
vital checks every 30 minutes until stable. Electrocardiograms
and chest radiographs should be obtained for all patients
presenting with tachycardia, chest pain, or shortness of breath.
The speciﬁc role of cardiac markers in the evaluation of these
patients has not been elucidated; however, given previously
documented mephedrone cardiac toxicity
13 and well-known
propensity of amphetamines to cause direct cardiac damage by
way of vasospasm and ischemia, it is prudent to approach the
treatment of patients with acute bath salt toxicity and chest pain
with at least the same level of caution as nonintoxicated
patientswith cardiac chest pain. A basic metabolicpanel should
be drawn for all patients to seek out hyponatremia and
metabolic acidosis. The risk of rhabdomyolysis is uncertain,
but in the setting of persistent agitation, obtaining a baseline
creatine kinasewould be reasonable. A complete blood count is
unlikely to aid in the workup of bath salt toxicity, although in
the setting of altered mental status, agitation, and hyperthermia
of unclear etiology, it may be improper to ignore.
Agitation can be controlled with benzodiazepines as ﬁrst-
line therapy. Other supportive measures, including ﬂuid
management and temperature control, may play signiﬁcant
roles in individual cases. More advanced ﬂuid management
techniques may be required for cases complicated by
hyponatremia or rhabdomyolysis. Seizures, should they occur,
would be expected to respond to medications acting through c-
aminobutyric acid promotion, such as benzodiazepines,
barbiturates, and propofol. Airway compromise, extreme
sedation needs, seizures evolving to status epilepticus, and
uncontrolled agitation all suggest the need for advanced airway
management.
A controversial portion of the workup for any patient
whose primary problem is exposure to a drug or poison is the
‘‘tox screen.’’ It should be noted that, in general, for emergency-
department decision making for the toxicologic patient, this
screening test is unhelpful.
40 This notwithstanding, there is
increasing precedent for detection of both mephedrone and
MDPV . The ﬁrst isolated mephedrone-related case report stated
that the substance was not identiﬁed by routine toxicologic
analysis, but subsequent reports had success with more
advanced testing.
2 Identiﬁcation of mephedrone from samples
seized in police raids has been recently described.
41 Both
mephedrone and MDPV have recently been identiﬁed in urine
samples by gas chromatography-mass spectrometry, and
mephedrone can be identiﬁed by liquid chromatography-mass
spectrometry.
42–45 MDPV has also been identiﬁed by nuclear
magnetic resonance spectroscopic analysis.
46 At least 1
commercial laboratory currently offers diagnostic testing on
urine for both via liquid chromatography-tandem mass
spectrometry with a reporting limit of 1.0 ng/mL.
47 Despite
these advances, a urine or blood toxicologic assessment
negative for amphetamines in theface of convincing history and
physical examination should not dissuade the astute EP from
undertaking care appropriate for a bath salt ingestion. As with
many emerging substances of abuse, little data are available to
describe the sensitivity of currently used immunoassays in
broad terms, and at this time it is likely that the clinical
assessment of the patient who has ingested bath salts will be
more sensitive for the diagnosis than a toxicologic screen.
CONCLUSION
There is a limited but building body of literature consisting
largely of case reports, case series, surveys, media releases, and
poison center data regarding mephedrone and MDPV toxicity.
Figure. US poison center calls for bath salts and synthetic
cannabinoids, 2010–2011 (Bailey, personal communication,
October 3, 2011).
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and the sparse provider data that exist all support the notion that
both compounds act to create a sympathomimetic toxidrome
akin to that of cocaine and certain amphetamines. Proposed
evaluation and management arise from experience and case
reports only, but are likely congruous with standard proposed
management of more well-known drugs such as cocaine,
methamphetamine, and MDMA. Epidemiologic data are
suggestive of a growing disease burden stemming from
markedly increasing popularity of these so-called legal highs.
Even in areas in which they have been banned, the problem of
their acute toxicity persists and should be recognized by the
well-prepared EP.
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